Date: 2025-09-06
A weighted SWOT analysis goes beyond a simple list of strengths, weaknesses, opportunities, and threats by assigning weights (importance) and ratings (company’s effectiveness in that factor). This produces weighted scores that help investors see where the real leverage lies.
Scoring Method
- Weight: Importance of the factor (0.0 to 1.0, total of all = 1.0 per quadrant)
- Rating: Agilent’s relative performance in that factor (1 = poor, 5 = excellent)
- Weighted Score = Weight × Rating
Strengths
| Strength | Weight | Rating | Weighted Score | Notes |
|---|---|---|---|---|
| Strong recurring revenue base (CrossLab + consumables = ~64% of revenue) | 0.25 | 5 | 1.25 | Stickiness, reduces cyclicality |
| Consistent profitability (≈18% net margin, >50% gross margin) | 0.20 | 4 | 0.80 | Above many peers |
| Strong balance sheet (current ratio 2.25, moderate D/E 0.54) | 0.20 | 4 | 0.80 | Financial flexibility |
| Shareholder returns (dividends + buybacks, −6.9% shares outstanding 5 yrs) | 0.15 | 4 | 0.60 | Management aligned |
| Global brand and broad portfolio (LSAG, DGG, ACG) | 0.20 | 4 | 0.80 | Diversified product/services |
| Total Strengths Weighted Score | 1.00 | – | 4.25 | High overall strength |
Weaknesses
| Weakness | Weight | Rating | Weighted Score | Notes |
|---|---|---|---|---|
| High valuation (P/E 30, EV/FCF ~38, PEGY ~4.9) | 0.30 | 2 | 0.60 | Expensive relative to growth |
| Growth inconsistency (3-yr CAGR 0.64%) | 0.25 | 2 | 0.50 | China and instrument cycles |
| Dependence on cyclical instrument sales (~36% of revenue) | 0.20 | 3 | 0.60 | Still exposed |
| Mid-range ROIC (~10%) not far above cost of capital | 0.15 | 3 | 0.45 | Not a wide value spread |
| Modest dividend yield (0.76%) | 0.10 | 3 | 0.30 | Attractive only as supplement |
| Total Weaknesses Weighted Score | 1.00 | – | 2.45 | Moderate weaknesses, valuation heavy |
Opportunities
| Opportunity | Weight | Rating | Weighted Score | Notes |
|---|---|---|---|---|
| Expansion in diagnostics, genomics, nucleic-acid solutions | 0.30 | 4 | 1.20 | Long-term secular growth |
| CrossLab services growth (mission-critical consumables & contracts) | 0.25 | 5 | 1.25 | Stable recurring cash flows |
| Aging populations driving pharma, biotech, and clinical testing demand | 0.20 | 4 | 0.80 | Structural tailwind |
| Selective M&A (e.g., BIOVECTRA CDMO entry) | 0.15 | 3 | 0.45 | Careful but not guaranteed |
| Growth in emerging markets outside China | 0.10 | 3 | 0.30 | Diversification potential |
| Total Opportunities Weighted Score | 1.00 | – | 4.00 | Strong growth runway |
Threats
| Threat | Weight | Rating | Weighted Score | Notes |
|---|---|---|---|---|
| Intense competition (Thermo Fisher, Danaher, Waters, Bruker, Shimadzu) | 0.30 | 3 | 0.90 | Larger peers can outspend |
| China demand weakness, regulatory environment | 0.25 | 2 | 0.50 | Current drag |
| Cyclical downturns in pharma/academic instrument budgets | 0.20 | 3 | 0.60 | Recurring risk |
| M&A integration risk ($1.46B spent in 5 yrs) | 0.15 | 3 | 0.45 | Returns uncertain |
| Currency fluctuations and global macro shocks | 0.10 | 3 | 0.30 | Hard to control |
| Total Threats Weighted Score | 1.00 | – | 2.75 | Manageable but real risks |
Interpretation
- Strengths Score (4.25) > Weaknesses Score (2.45): The company’s internal position is robust, especially recurring revenue, margins, and capital returns.
- Opportunities Score (4.00) > Threats Score (2.75): External environment is more favorable than risky, especially in diagnostics and services.
- The main drag on the story is valuation. At thirty times earnings and nearly thirty-eight times free cash flow, investors today are paying for strengths and opportunities upfront without margin of safety.
Weighted SWOT Verdict
Agilent is a high-quality compounder with durable advantages. Its recurring revenue mix, global brand, and stable cash flow generation earn high strength scores. Opportunities in diagnostics, services, and biotech tailwinds are significant. However, the rich valuation and cyclical exposure to instruments weigh down the investment case.
As a value investor, the conclusion is clear: Agilent should be on the watchlist, but not bought aggressively above intrinsic value. The company is attractive closer to one hundred dollars per share, where strengths and opportunities outweigh risks with a margin of safety.
Disclaimer: This analysis is for informational purposes only and does not constitute investment advice. Always perform your own due diligence or consult with a financial advisor before making investment decisions.
